Gene Synthesis
De novo gene synthesis technologies enable the development and optimization of antigen-presenting viral genes for safe and rapid vaccine development. GENEWIZ’s synthetic DNA solutions can also be utilized to rapidly produce standard/controls for the development of coronavirus diagnostic assays.
Oligo
Scientists can now order primers and qPCR probes approved by the Centers for Disease Control and Prevention (CDC), World Health Organization (WHO), and Chinese government for rapid identification of the virus.
Please see the available list of primers and qPCR probes here. HPLC purified COVID-19 primers and qPCR probes are available for direct order through our e-commerce platform. Note, all primers and qPCR probes are Research Use Only (RUO) and not for use in diagnostics.
Next Generation Sequencing
NGS continues to play an indispensable role in characterizing and understanding the rapid spread of the coronavirus across the globe. Technologies such as whole genome sequencing and targeted amplicon sequencing can help discover, identify, and monitor pathogenic sequences.
GENEWIZ’s NGS service portfolio is uniquely positioned to help you identify and uncover known and emerging viruses.
PCR + Sanger Services
GENEWIZ’s PCR + Sanger workflows enable the research community to understand emerging infections and advance vaccine development at the RUO level. These assays can facilitate basic research, cell line development and characterization, viral genome confirmation, antibody HC/LC confirmation, and more.
Sanger Sequencing
GENEWIZ’s award-winning Sanger sequencing services are crucial for advancing COVID-19 research and vaccine development from viral strain identification to antigen sequence verification at the RUO, GLP, and CLIA service levels.
Plasmid DNA Prep
GENEWIZ’s plasmid preparation services enable rapid scale-up of viral genes to support therapeutic research and development of a COVID-19 vaccination.
GLP
Our GLP services comply with 21 CFR, Part 58, and use PCR + Sanger sequencing to assist with the preclinical development, clinical trials, and post-manufacturing phases of therapeutics and vaccine development pipelines. Among these, we offer GLP-compliant plasmid preparation, plasmid sequence confirmation, viral genome verification, and gDNA/cDNA/RNA confirmation.
CAP/CLIA
GENEWIZ's CAP-accredited and CLIA-certified clinical laboratory operates NGS and Sanger workflows to support clinical trials.
Our CLIA-certified services include pre-validated whole genome and exome sequencing, as well as custom validations.
Our CLIA environment capabilities include RNA-Seq, metagenomics, and variant confirmation RUO workflows in a CLIA environment.
